Measures taken against Rising Cervical Cancer

1. At a Glance

• Cervical cancer is the 2nd most common cancer among Indian women; India accounts for a major share of global burden, estimated 127,526 new cases (2023) and 79,906 deaths [4].
• Government response combines HPV vaccination of adolescent girls and population-based screening under NP-NCD at Ayushman Aarogya Mandirs [1][2].
• UPSC relevance: GS-II (health governance), GS-III (S&T, indigenous vaccine), and current affairs of major NHM/NCD push.

2. Why in the News

• 8.73 crore women screened for cervical cancer as on 17 Feb 2026 per the National NCD Portal (MoHFW release, 10 Mar 2026) [1].
• PM Modi launched the Nationwide HPV Vaccination Drive for 14-year-old girls from Ajmer, Rajasthan on 28 Feb 2026 [3].
• India targets ~1.15 crore girls (age 14) for free HPV vaccination at government health facilities [2].

3. Background & Evolution

• WHO Global Strategy for Cervical Cancer Elimination adopted by World Health Assembly in August 2020 with 90-70-90 targets by 2030 [5].
• India's screening for cervical cancer rolled out under National Programme for Prevention and Control of NCDs (NP-NCD), MoHFW, using Visual Inspection with Acetic Acid (VIA) for women 30-65 yrs [2].
• Operation Digital Health via National NCD Portal tracks screenings [1].
• Union Budget 2024-25 (FM Nirmala Sitharaman) announced encouragement of HPV vaccination for girls 9-14 yrs; campaign operationalised in 2026 [2][3].

4. Core Static Facts

• Implementing ministry: Ministry of Health & Family Welfare (MoHFW) [1].
• Programme: NP-NCD under National Health Mission; delivered at Ayushman Aarogya Mandirs (AAM-PHCs), CHCs, Sub-Centres [1].
• Vaccine used: Gardasil (quadrivalent) — protects against HPV types 6, 11, 16, 18; single-dose 93-100% effective vs oncogenic types [2]. India's indigenous CERVAVAC (Serum Institute) is also approved.
• Target age (vaccination campaign): 14-year-old girls at government facilities [1][3].
• Screening age band: 30-65 years women via VIA at AAMs [2].
• Burden (2023): 127,526 new cases; ASR incidence 17.7/100,000; 79,906 deaths; mortality 11.2/100,000 [4].
• Screening coverage: 8.73 crore women screened cumulatively (Feb 2026) [1]; historically <1 in 10 women screened in last 5 yrs [4].

5. Multi-Dimensional Analysis

Social / Gender

• Targets a women-specific cancer; addresses gendered access gaps to preventive care [4].
• AAM-based delivery reaches rural/tribal women previously excluded [2].

Scientific / Technological

• Shift from cytology to VIA (low-cost) for mass screening; single-dose HPV schedule backed by IARC evidence [2][4].
• Indigenous CERVAVAC reduces import dependence on Gardasil/Cervarix.

Administrative

• Two-track strategy (primary prevention via vaccine + secondary via screening) requires Centre-State coordination via NHM PIPs.
• National NCD Portal acts as MIS for real-time tracking [1].

Health-Economic

• WHO modelling shows India could eliminate cervical cancer by 2063 if 90-70-90 reached by 2034 with multi-age catch-up [4].
• Free public-sector vaccination removes ~₹2000-4000/dose cost barrier for households.

6. Recent Developments (last 12-18 months)

• 28 Feb 2026: PM launched nationwide HPV vaccination drive at Ajmer [3].
• 10 Mar 2026: MoHFW PIB release reports 8.73 cr women screened [1].
• 2026: Union Health Minister J.P. Nadda addressed WHO HQ reaffirming India's commitment to cervical cancer elimination [S2 via search index].
• Union Budget 2024-25: announced vaccination push for girls 9-14 yrs.

7. Prelims Hooks

• HPV vaccine used in national campaign — Gardasil (quadrivalent) covering HPV 6, 11, 16, 18 [2].
• Nationwide HPV drive targets 14-year-old girls (not 9-14 entire band yet in campaign) [1].
• Launched from Ajmer, Rajasthan on 28 Feb 2026 [3].
• Cervical cancer screening uses VIA (Visual Inspection with Acetic Acid) for women 30-65 yrs [2].
• Delivered at Ayushman Aarogya Mandirs (rebranded HWCs) under NP-NCD [1].
• Tracked by National NCD Portal under MoHFW [1].
• WHO 90-70-90 strategy adopted by WHA in August 2020 [5].
• India's estimated cervical cancer deaths (2023): ~79,906 [4].
• ASR incidence in India: 17.7 per 100,000 women [4].
• Data source for cancer incidence/mortality: NCDIR-National Cancer Registry Programme under ICMR [1].
• Indigenous HPV vaccine: CERVAVAC by Serum Institute of India.
• WHO elimination threshold: <4 cases per 100,000 women.

8. Mains Relevance

• GS-II: Issues relating to development & management of Social Sector/Health; Government policies & interventions.
• GS-III: Science & Technology — indigenisation of vaccines; Awareness in biotech.
• Sample stems: 1. "Discuss the multi-pronged strategy of the Government of India to combat cervical cancer in light of the WHO 90-70-90 elimination targets." (GS-II, 250 words) 2. "Evaluate the role of Ayushman Aarogya Mandirs in operationalising population-based NCD screening in India." (GS-II) 3. "How can indigenous vaccines like CERVAVAC accelerate India's public health goals? Examine challenges in nationwide HPV vaccine rollout." (GS-III)

9. Related Topics to Study Next

• National Health Mission (NHM) — umbrella scheme.
• Ayushman Bharat – PMJAY & Aarogya Mandirs — delivery platform.
• Universal Immunisation Programme (UIP) — HPV's potential inclusion debate.
• National Cancer Registry Programme (ICMR-NCDIR) — data backbone.
• WHO Global Strategy 2020 & SDG-3 — international anchor.
• CERVAVAC / Serum Institute — indigenous biotech case study.
• Non-Communicable Diseases burden (ICMR-INDIAB, GBD) — wider canvas.
• Mission Indradhanush — vaccination delivery analogue.

10. Common Errors / Trap Areas

• HPV vaccine is not yet in the Universal Immunisation Programme — it is delivered through a separate campaign; do not conflate [4].
• Gardasil is quadrivalent (6,11,16,18); a 9-valent version exists — exam may test composition.
• Screening uses VIA, not Pap smear, in public programme at primary level.
• Programme is under NP-NCD (MoHFW), not under Ministry of Women & Child Development.
• WHO targets are 90-70-90, not 90-90-90 (the latter relates to HIV/AIDS).